Natera Targets $2Bln Revenue In 2025

There appears to be no slowing down for Natera Inc. (NTRA), with the diagnostics company once again revising up its revenue outlook for 2025.

The company offers cell-free DNA testing, with a focus on oncology, women's health, and organ health.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com